Levetiracetam for the Management of Levodopa-Induced Dyskinesias in Parkinson's Disease
Loading...
Date
Authors
Stathis, P.
Konitsiotis, S.
Tagaris, G.
Peterson, D.
Valid-Pd Study Grp
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Type
Type of the conference item
Journal type
peer-reviewed
Educational material type
Conference Name
Journal name
Movement Disorders
Book name
Book series
Book edition
Alternative title / Subtitle
Description
The efficacy and safety of levetiracetam (LEV), administered for management of levodopa-induced dyskinesias (LID) in Parkinson's disease (PD), was examined using a multicenter, double-blind, placebo-controlled, parallel groups, crossover trial. Because of having a period effect, data after crossover point was excluded from analysis. Levodopa-treated PD participants with LID (n = 38) received LEV 500 mg/day, were assessed, titrated to 1,000 mg/day and reassessed, before and after crossover. The placebo group followed the same routine. Primary efficacy was defined from percent change in "On with LID" time from patient diaries. Secondary efficacy assessment used "On without LID," "Off" time, unified PD rating scale (UPDRS), clinical global impression (CGI), and Goetz dyskinesia scale after levodopa challenge. Safety measures were also performed. On with LID time decreased 37 minutes (95% confidence interval [CI] 0.59, 7.15; P = 0.02) at 500 mg/day, 7.85% 75 minutes (95% CI 3.3, 12.4; P = 0.002) at 1,000 mg/day. On without LID time increased by 46 minutes (95% CI -1.55, -0.03; P = 0.04) at 500 mg/day and 55 minutes (95% CI -10.39, -1.14; P = 0.018) at 1,000 mg/day. UPDRS 32 showed decreased dyskinesia duration mean change 0.35 (95% CI 0.09, 0.5; P = 0.009) at 1,000 mg/day. CGI showed LID decreased by 0.7 (95% CI 0.21, 1.18; P = 0.006) at 1,000 mg/day. Patient diaries and UPDRS show no increase in Off time. This exploratory trial provides evidence that LEV in 1,000 mg/day, slowly titrated, could be useful in improving LID as was assessed with patient diaries, UPDRS, and CGI scales, safely, with minimal side effects. (C) 2010 Movement Disorder Society
Description
Keywords
levodopa-induced dyskinesias, parkinson's disease, levetiracetam, quality-of-life, l-dopa, motor complications, open-label, mechanisms, strategies, agonists, model
Subject classification
Citation
Link
<Go to ISI>://000288461800011
http://onlinelibrary.wiley.com/store/10.1002/mds.23355/asset/23355_ftp.pdf?v=1&t=h0anbdf5&s=b7a17a81ea5c3298789000efc1115bc488d2ec5e
http://onlinelibrary.wiley.com/store/10.1002/mds.23355/asset/23355_ftp.pdf?v=1&t=h0anbdf5&s=b7a17a81ea5c3298789000efc1115bc488d2ec5e
Language
en
Publishing department/division
Advisor name
Examining committee
General Description / Additional Comments
Institution and School/Department of submitter
Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής